

# News

**FOR IMMEDIATE RELEASE:**

**Cerestim starts TSB Biocatalyst study.**

*London, UK – July 1st, 2014* – Cerestim Ltd is pleased to announce that it has begun its recently awarded TSB Biocatalyst study.

Following sign-off of its project plans and forecasts by the TSB, Cerestim has started the 5 strands of this study. These strands encompass: a clinical application review of scientific results, healthcare economics and stakeholder interviews; a business opportunity evaluation with regulatory pathway determination, market research and an analysis of risks; an IP mapping study; a neuroimaging study and finally an R&D scoping determination in preparation for product development.

Ian Harris, CEO, said “We are very pleased to partner with the TSB on this study. We will have answered many of the important questions facing us by the time of its completion. This will provide us with a very strong platform upon which to build the next stages of this exciting opportunity.”

Cerestim is engaged in developing its scientific and commercialisation strategy; fund raising; developing academic and commercial partners and preparing IP. The title of the TSB study is ‘Feasibility assessment of the opportunity for the use of transcranial cranial stimulation for the treatment of brain disorders’. The study is part funded by the Technology Strategy Board.

The Technology Strategy Board is the UK’s innovation agency and part of the Department for Business Innovation & Skills. More information can be found on <https://www.innovateuk.org/biomedical-catalyst>.

Contact:

Ian Harris, Cerestim  
[ian.harris@cerestim.com](mailto:ian.harris@cerestim.com)

###